$ISRG

GUTHART GARY S sold $4.0M of ISRG (indirect holdings)

GUTHART GARY S sold 10,000 indirectly-held shares of INTUITIVE SURGICAL INC (ISRG) at $400.00 ($4.00M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GUTHART GARY S
Published Aug 12, 2026, 5:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 10,000 shares at $400/share on 2026-08-11, filed on 2026-08-12, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may briefly react to insider selling headlines, but 10b5-1 context usually limits fundamental implications.

03

What to watch

The filing does not indicate reasons for sale, and the indirect ownership structure plus 10b5-1 timing can make the signal less informative than discretionary sales.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Form 4 shows director GUTHART GARY S sold 10,000 ISRG shares on 2026-08-11 for about $4.0M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The transaction is an open-market sale by a director, explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Even with a 10b5-1 plan, large dollar sales can still be interpreted by some traders as a mild bearish signal, especially if paired with other negative catalysts not mentioned here.

Key entities

  • INTUITIVE SURGICAL INC

    Company whose shares were sold in the reported Form 4 transaction.

  • GUTHART GARY S

    Director who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGMed

Why is Intuitive Surgical stock gaining today?

Investing.com reports Intuitive Surgical (ISRG) rose about 0.8% in pre-open after Oppenheimer upgraded it to Outperform from Perform and set a $500 price target. Oppenheimer and Bank of America Securities issued Buy ratings, citing da Vinci’s competitive position and Per Click Model. The article also notes ISRG Q2 2026 EPS of $2.80 vs $2.51 consensus.

$JNJMed

Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?

Johnson & Johnson (JNJ) received FDA De Novo authorization for its OTTAVA robotic surgical system and is entering U.S. soft-tissue robotic surgery. OTTAVA is authorized for multiple upper-abdominal procedures, with a selective U.S. launch and an ongoing inguinal hernia trial. The article compares JNJ’s entry with Intuitive Surgical (ISRG) and its da Vinci 5 installed base.

$ISRGMed

Intuitive Surgical's 34% Plunge Splits Analysts: DCF Says Fair Value, Bernstein Sees 83% Upside — BigGo Finance

Intuitive Surgical (ISRG) shares fell 34% YTD after guidance for 2026 da Vinci procedure growth of 13.5% to 15.5% versus about 18% expected. The stock trades at $373.71, below an average analyst target of $477.25. A DCF estimates fair value near $408, while Bernstein cites an $685 target. Q2 2026 results: non-GAAP EPS $2.80, revenue $2.89B.

$ISRGMed

UBS starts medtech coverage, favors Intuitive Surgical and Enovis By Investing.com

UBS initiated coverage of four U.S. medtech firms. It assigned Buy ratings to Intuitive Surgical (ISRG) with a $500 price target and Enovis (ENOV) with a $51 target, citing growth drivers and improving fundamentals. UBS gave Inspire Medical Systems (INSP) a Sell rating with a $39 target and Integra LifeSciences (IART) a Neutral rating with a $19 target, citing competition, reimbursement and limited catalysts.

$UNHMed

UnitedHealth Group Incorporated (UNH) and Intuitive Surgical, Inc. (ISRG) Just Showed Why Beating Estimates Isn’t Enough

UnitedHealth (UNH) and Intuitive Surgical (ISRG) both beat July earnings estimates. UNH reported adjusted EPS of $6.38 vs $4.90 expected, revenue of $112B, and raised full-year profit guidance to $19.50-$20. ISRG reported $2.89B revenue and $2.80 EPS vs $2.50 expected, but shares fell after guidance implied slower procedure growth near the middle of its range.